Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines

Radiation Research

Volumn 166, Issue 4, 2006, Pages 600-610

  Amine, Abdessamad ^a   Vozenin Brotons, Marie Catherine ^a,b,d   Abdulkarim, Bassam ^a,c   Violot, Dominique ^a   Aubel, Corinne ^a   Bourhis, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^c UNIVERSITY OF ALBERTA   (Canada)

^d IGR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; MATRIGEL; MESSENGER RNA; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; VEGF GENE; WESTERN BLOTTING;

ANGIOGENIC PROTEINS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOSINE; DOWN-REGULATION; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHONIC ACIDS; RADIATION DOSAGE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749170109     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0423.1     Document Type: Article

References (29)

1. P. A. Lazo, The molecular genetics of cervical carcinoma. Br. J. Cancer 80, 2008-2018 (1999).
2. H. zur Hausen, Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92, 690-698 (2000).
3. B. Abdulkarim, S. Sabri, E. Deutsch, H. Chagraoui, L. Maggiorella, J. Thierry, F. Eschwege, W. Vainchenker, S. Chouaib and J. Bourhis, Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21, 2334-2346 (2002).
4. N. Sirianni, J. Wang and R. L. Ferris, Antiviral activity of cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol. 41, 423-428 (2005).
5. T. Cihlar and M. S. Chen, Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50, 1502-1510 (1996).
6. E. De Clercq, Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16, 569-596 (2003).
7. J. Alzarini, J. F. Navé, M. A. Becker, M. Tatibana and E. De Clercq, Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleosides Nucleotides 14, 1861-1871 (1995).
8. A. Merta, I. Votruba, J. Jindrich, A. Hol, T. Cihlar, I. Rosenberg, M. Otmar and T. Y. Herve, Phosphorylation of 9-(2-phosphonomethoxyethyl)-adenine by AMP(dAMP) kinase from L1210. Biochem. Pharmacol. 44, 2067-2077 (1992).
9. E. Toussaint-Smith, D. B. Donner and A. Roman, Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 23, 2988-2995 (2004).
10. K. Smith-McCune, Y. H. Zhu, D. Hanahan and J. Arbeit, Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res. 57, 1294-1300 (1997).
11. O. Lopez-Ocejo, A. Viloria-Petit, M. Bequet-Romero, D. Mukhopadhyay, J. Rak and R. S. Kerbel, Oncogenes and tumor angiogenesis: The HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19, 4611-4620 (2000).
12. L. Zhang, D. Yu, M. Hu, S. Xiong, A. Lang, L. M. Ellis and R. E. Pollock, Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60, 3655-3661 (2000).
13. K. Smith-McCune and N. Weidner, Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 54, 800-804 (1994).
14. A. J. Guidi, G. Abu-Jawdeh, B. Berse, R. W. Jackman, K. Tognazzi, H. F. Dvorak and L. F. Brown, Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Natl. Cancer Inst. 87, 1237-1245 (1995).
15. K. Tokumo, J. Kodama, N. Seki, Y. Nakanishi, Y. Miyagi, S. Kamimura, M. Yoshinouchi, H. Okuda and T. Kudo, Different angiogenic pathways in human cervical cancers. Gynecol. Oncol. 68, 38-44 (1998).
16. C. M. West, R. A. Cooper, J. A. Loncaster, D. P. Wilks and M. Bromley, Tumor vascularity: A histological measure of angiogenesis and hypoxia. Cancer Res. 61, 2907-2910 (2001).
17. R. A. Cooper, D. P. Wilks, J. P. Logue, S. E. Davidson, R. D. Hunter, S. A. Roberts and C. M. West, High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin. Cancer Res. 4, 2795-2800 (1998).
18. J. A. Loncaster, R. A. Cooper, J. P. Logue, S. E. Davidson, R. D. Hunter and C. M. West, Vascular endothelial growth factor (VEGF) expression as a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br. J. Cancer 83, 620-625 (2000).
19. H. Hawighorst, P. G. Knapstein, M. V. Knopp, W. Weikel, G. Brix, I. Zuna, S. O. Schonberg, M. Essig, P. Vaupel and G. Van Kaick, Uterine cervical carcinoma: Comparison of standard pharmacokinetic analysis of time-intensity curves for tumor assessment of tumor angiogenesis and patient survival. Cancer Res. 58, 3598-3602 (1998).
20. M. Ueda, Y. Terai, K. Kuomagai, K. Ueki, H. Yamaguchi, D. Akise and M. Ueki, Vascular endothelial growth factor C gene expression is closely related to invasive phenotype in gynaecologic tumor cells. Gynecol. Oncol. 82, 162-166 (2001).
21. J. Kodama, N. Seki, K. Tokumo, A. Hongo, Y. Miyagi, M. Yoshinouchi, H. Okuda and T. Kudo, Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur. J. Cancer 35, 485-489 (1999).
22. I. Hashimoto, J. Kodama, N. Seki, A. Hongo, Yoshinouchi, H. Okuda and T. Kudo, Vascular endothelial growth factor C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br. J. Cancer 85, 93-97 (2001).
23. K. Butz, T. Ristriani, A. Hengstermann, C. Denk, M. Scheffner and F. Hoppe-Seyler, siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938-5945 (2003).
24. A. Albini, G. Allavena, A. Melchiori, F. Giancotti, H. Richter, P. M. Comoglio, S. Parodi, G. R. Martin and G. Tarone, Chemotaxis of 3T3 and SV3T3 cells to fibronectin is mediated through the cell-attachment site in fibronectin and a fibronectin cell surface receptor. J. Cell Biol. 105, 1867-1872 (1987).
25. M. Klagsbrun and S. Soker, VEGF/VPF: The angiogenesis factor found? Curr. Biol. 3, 699-702 (1993).
26. N. Ferrara, Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55, 15-35 (2000).
27. D. Hanahan and J. Folkman, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
28. D. Hanahan, Signaling vascular morphogenesis and maintenance. Science 277, 48-50 (1997).
29. D. Mukhopadhyay, L. Tsiokas and V. P. Sukhatme, Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55, 6161-6165 (1995).